These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 16093780)

  • 1. Immunotherapy for thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM; Lian EC
    N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Solenthaler M; Lämmle B
    Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
    Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.
    Furlan M; Lämmle B
    Baillieres Clin Haematol; 1998 Jun; 11(2):509-14. PubMed ID: 10097823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
    Sadler JE
    Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
    Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
    Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic relapsing thrombotic thrombocytopenic purpura due to a deficiency of von Willebrand factor-cleaving protease activity.
    Stark GL; Wallis JP; Allford SL; Hanley J
    Br J Haematol; 2002 Apr; 117(1):251-2. PubMed ID: 11918566
    [No Abstract]   [Full Text] [Related]  

  • 12. von Willebrand factor and thrombotic thrombocytopenic purpura.
    Raife TJ; Montgomery RR
    Curr Opin Hematol; 2000 Sep; 7(5):278-83. PubMed ID: 10961577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
    Yarranton H; Machin SJ
    Curr Opin Neurol; 2003 Jun; 16(3):367-73. PubMed ID: 12858075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.
    Tsai HM; Shulman K
    Eur J Haematol; 2003 Mar; 70(3):183-5. PubMed ID: 12605663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
    Galbusera M; Bresin E; Noris M; Gastoldi S; Belotti D; Capoferri C; Daina E; Perseghin P; Scheiflinger F; Fakhouri F; Grünfeld JP; Pogliani E; Remuzzi G
    Blood; 2005 Aug; 106(3):925-8. PubMed ID: 15827129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
    Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
    Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
    Furlan M
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy for refractory thrombotic thrombocytopenic purpura.
    Gutterman LA; Kloster B; Tsai HM
    Blood Cells Mol Dis; 2002; 28(3):385-91. PubMed ID: 12367582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.